Hemodialysis patients. Cloudy (hemodialysis) (peritoneal) dialysis effluent
Conditions
Interventions
Intervention 1: Intervention group: Colecalciferol drug of Iran Hormone Pharmaceutical Company (orally pearl and capsule-like once a week (50000 units) for 12 weeks). Intervention 2: Control group: Pl
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 70 Years
Inclusion criteria
Inclusion criteria: Consent to participate in the study Age range of 15-70 years Dialysis patients undergoing blood dialysis for more than 3 months. Patients undergoing hemodialysis 3 times a week. Patients undergoing blood hemodialysis that their 25-hydroxyvitamin D concentration is less than 30 ng/ml.
Exclusion criteria
Exclusion criteria: Dissatisfaction to participate in the study Patients with active infection Patients with history of renal transplantation Patients with any history of malignancy Presence of hyperphosphatemia (Blood phosphor >7) History of parathyroidectomy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of lipid profile. Timepoint: Before intervention and after medication. Method of measurement: Biochemical methods.;Evaluation of serum levels of 25OHD. Timepoint: Before intervention and after medication. Method of measurement: Biochemical methods.;Evaluation of parathyroid hormone (PTH) levels. Timepoint: Before intervention and after medication. Method of measurement: Biochemical methods.;Evaluation of Klotho levels. Timepoint: Before intervention and after medication. Method of measurement: Biochemical methods.;Evaluation of CRP levels. Timepoint: Before intervention and after medication. Method of measurement: Biochemical methods.;Evaluation of MDA levels. Timepoint: Before intervention and after medication. Method of measurement: Biochemical methods. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Hamid Taybi Khosroshahi
Tabriz University of Medical Sciences
Outcome results
None listed